Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

The development and future of the NCRI

NCRI 2011

Published: 11 Nov 2011

Views: 3575

Rating:

Save

Prof Kenneth Calman - University of Glasgow, UK

Prof Ken Calman and Prof Gordon McVie discuss the development of NCRI and how its cancer research database monitors all areas of NCRI’s cancer research and allows for important evaluations to take place.

The pair also discuss the controversy of the presence of pharma in NCRI’s early development and the advantages of patient input in NCRI.

Related Videos

The case for global gender-neutral HPV vaccination

Peter Baker, Global Action on Men's Health (United Kingdom)

The case for global gender-neutral HPV vaccination ( Peter Baker, Global Action on Men's Health (United Kingdom) )

Cooperative training for medical staff in Côte d'Ivoire: The national radiotherapy and medical oncology center project

Dr Chong Woo Yoo - National Cancer Center, Seoul, Republic of Korea

Cooperative training for medical staff in Côte d'Ivoire: The national radiotherapy and medical oncology center project ( Dr Chong Woo Yoo - National Cancer Center, Seoul, Republic of Korea )

Transforming cancer care in Africa: The ECHO project

Dr Daniel Osei-Fofie - Robert Mangaliso Sobukwe, Kimberley, South Africa

Transforming cancer care in Africa: The ECHO project ( Dr Daniel Osei-Fofie - Robert Mangaliso Sobukwe, Kimberley, South Africa )

Predicting tumour mutations from pathology images may help increase personalised medicine utilisation

Dr Rom Leidner - Providence Cancer Institute, Portland, USA

Predicting tumour mutations from pathology images may help increase personalised medicine utilisation ( Dr Rom Leidner - Providence Cancer Institute, Portland, USA )

Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC

Dr Marina Garassino - University of Chicago, Chicago, USA

Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC ( Dr Marina Garassino - University of Chicago, Chicago, USA )

ESMO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

Durable responses in aRCC, how do we optimise treatment?

Prof Roberto Iacovelli and Prof Viktor Grünwald

Durable responses in aRCC, how do we optimise treatment? ( Prof Roberto Iacovelli and Prof Viktor Grünwald )

Perspectives on advance care planning for advanced cancer in the Philippines

Dr Sachiko Estreller - Cordillera Hospital of the Divine Grace, Benguet, Philippines

Perspectives on advance care planning for advanced cancer in the Philippines ( Dr Sachiko Estreller - Cordillera Hospital of the Divine Grace, Benguet, Philippines )

Preview: World Cancer Congress 2024

Union for International Cancer Control

Preview: World Cancer Congress 2024 ( Union for International Cancer Control )

More from ecancer